- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- ’10 Americas:’ Health Disparities Mean Life Expectancy Varies Across U.S.
- Short-Term Hormone Therapy for Menopause Won’t Harm Women’s Brains
- Could a Vitamin Be Effective Treatment for COPD?
- Woman Receives World’s First Robotic Double-Lung Transplant
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Meds Like Ozempic Are Causing Folks to Waste More Food
- Fibroids, Endometriosis Linked to Shorter Life Spans
- E. Coli Fears Spur Recall of 167,000 Pounds of Ground Beef
Health Highlights: Jan. 18, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Gluten-Free Chicken Nuggets Recalled by Perdue Foods
Possible wood contamination has led to the recall of more than 68,000 pounds of gluten-free chicken nuggets from Perdue Foods, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) says.
The agency said there are no confirmed cases of illness linked with the ready-to-eat chicken nuggets, which were produced on Oct. 25, 2018, CNN reported.
“The problem was discovered when the firm received three consumer complaints that wood was found in the product,” according to a FSIS statement.
The agency said that consumers with the recalled chicken nuggets should throw them away or return them to the place of purchase, CNN reported.
——
FDA Panel Splits Vote on New Diabetes Drug
A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.
Despite that result, the FDA is expected to decide by the end of March whether the drug — sotagliflozin (Zynquista) should be made available in the United States, The New York Times reported.
The drug, used along with insulin, is a once-daily pill meant to help type 1 diabetes patients manage their blood sugar levels.
Some of the advisory panel members voted against Zynquista because it carries an increased risk of a dangerous condition called diabetic ketoacidosis, which occurs when the body doesn’t get enough insulin, The Times reported.
Drug makers Sanofi and Lexicon Pharmaceuticals said they’ll continue to work with the FDA through the review process for the drug.
Copyright © 2024 HealthDay. All rights reserved.